Patents Examined by Changhwa J. Cheu
  • Patent number: 10571467
    Abstract: In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNF? drug during the course of anti-TNF? drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNF? drug in a subject during the course of anti-TNF? drug therapy. Systems for predicting anti-TNF? drug levels and the likelihood of autoantibody formation during the course of anti-TNF? drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNF? drug therapy.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Prometheus Biosiences, Inc.
    Inventors: Sharat Singh, Venkateswarlu Kondragunta
  • Patent number: 10571473
    Abstract: Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: February 25, 2020
    Assignee: Washington University
    Inventor: Robi D. Mitra
  • Patent number: 10571476
    Abstract: Disclosed are methods for screening for candidate compounds for hydrating the skin. The compounds selected according to the methods disclosed therein stimulate the intra-cellular amount and/or activity of TonEBP in keratinocytes. Preferably, the selected compounds induce a stimulation of at least 20%, preferably at least 50%, preferably at least 100% of the activity and/or intra-cellular amount of TonEBP.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: February 25, 2020
    Assignee: CHANEL PARFUMS BEAUTE
    Inventors: Emmanuelle Bouissou-Cadio, Gaelle Gendronneau, Francois Lejeune, Irina Berlin
  • Patent number: 10571477
    Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.
    Type: Grant
    Filed: July 4, 2015
    Date of Patent: February 25, 2020
    Assignee: Protagen GmbH
    Inventors: Petra Budde, Peter Schulz-Knappe, Angelika Lüking, Martin Gamer
  • Patent number: 10564151
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 18, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Patent number: 10551394
    Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: February 4, 2020
    Assignee: ZORA BIOSCIENCES OY
    Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
  • Patent number: 10539555
    Abstract: This disclosure provides a method for determining male fertility status. The method comprises determining GM1 localization patterns following induced sperm capacitation, identifying the percentage of various patterns, particularly the ratio of [(AA+APM)/total number of GM1 localization patterns] and determining if the percentage of certain GM1 localization patterns in response to induced capacitation is altered. Based on the change in the percentage of localization patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 21, 2020
    Assignee: ANDROVIA LIFESCIENCES, LLC
    Inventors: Alexander J. Travis, Cristina Cardona, Melissa A. Moody, Alana J. Simpson, G. Charles Ostermeier
  • Patent number: 10539574
    Abstract: A method for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue includes: a) treating a tissue sample with a protease and b) testing the protease-treated tissue sample for the presence of protease-resistant fragments of type II collagen and/or type I collagen. Methods can be carried out for preparing a cartilage cell culture, and for preparing a cartilage cell-loaded implant. Protease-resistant fragments of type II collagen and/or type I collagen can be used for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue. A kit can be used for carrying out the methods.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 21, 2020
    Assignee: TETEC Tissue Engineening Technologies AG
    Inventors: Karin Benz, Christian Freudigmann, Christoph Gaissmaier, Jochen Hecky, Jürgen Mollenhauer
  • Patent number: 10539564
    Abstract: Methods, compositions, and reaction mixtures are provided for identifying a T cell receptor (TCR) and an epitope peptide that specifically binds the TCR. Methods, compositions, and reaction mixtures are also provided for identifying a plurality of T cell receptors and corresponding epitope peptides that specifically bind the T cell receptors. In some cases, the plurality of T cell receptors and corresponding epitope peptides can be identified in a highly parallel manner.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: January 21, 2020
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Jan Berka, Sri Paladugu
  • Patent number: 10533992
    Abstract: Unlike a conventional method for evaluating a degree of ultraviolet protection through visual evaluation, the disclosed method for measuring a sunlight protection function can accurately and objectively measure and determine a degree of sunlight protection by measuring a change due to a material to be measured with respect to an expression amount of skin tissue antimicrobial peptides (AMPs) in skin cells, which decrease from exposure to sunlight, and/or a generation amount of S-nitrosylated protein. Additionally, the disclosed measurement method can determine whether blue/violet light of wavelengths of 400-500 nm, which induces the most skin damage among visible rays, is blocked and provide a more specified sunlight protection effect evaluation result. Moreover, by using the disclosed measurement method, a degree of sunlight protection can be indexed, and a sunlight protection composition for protecting normal skin from the blue/violet light can be provided.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: January 14, 2020
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Hyoung June Kim, Min Sik Choi, Ji Yong Jung, Ju Yearl Park, Tae Ryong Lee, Dong Wook Shin, Eui Dong Son, Min Jung Chae
  • Patent number: 10527633
    Abstract: Use of prostacyclin or an analogue thereof for treatment of a new medical indication in acute critically ill patients, in particular acute critically ill patients with systemic endothelial damage, a biomarker for identifying individuals that have a new medical indication, and a method for identifying a new medical indication.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: January 7, 2020
    Assignee: ENDOTHEL PHARMA APS
    Inventors: Sisse Rye Ostrowski, Pär Ingemar Johansson
  • Patent number: 10527630
    Abstract: The invention relates methods for detecting antibody-secreting B-cells specific for at least an HLA in a subject. The invention also relates to kits for developing said methods and to the use of said methods for determining the risk of a subject having humoral rejection against an allogeneic transplant, for determining the risk of a subject of suffering endarteritis associated with post-transplant humoral rejection after allogeneic organ or tissue transplant, for selecting a subject to receive a transplant, and for determining the presence of humoral sensitization against HLA.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: January 7, 2020
    Assignee: Institut D'Investigació Biomèdica de Bellvitge (IDIBELL)
    Inventors: Oriol Bestard Matamoros, Marc Lúcia Perrez, Josep Maria Grinyó Boira, Josep Maria Cruzado Garrit, Joan Torras Ambros
  • Patent number: 10526418
    Abstract: Compositions of modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: January 7, 2020
    Assignee: The Penn State Research Foundation
    Inventor: Yuguang Shi
  • Patent number: 10520505
    Abstract: Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 31, 2019
    Assignee: BioCardia, Inc.
    Inventors: Peter Altman, Cheryl Wong Po Foo
  • Patent number: 10509044
    Abstract: The present invention provides a method for predicting whether a human patient 65 years of age or older is at increased risk for developing heart failure, comprising obtaining the results of an assay that measures levels of NT-proBNP and/or cardiac troponin T in a specimen from the patient wherein an increased NT-proBNP and/or cardiac troponin T level compared to levels in a control indicate an increased risk for developing heart failure.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: December 17, 2019
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, BOARD OF REGENT, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Christopher Defilippi, Stephen Seliger, James De Lemos, Robert H. Christenson
  • Patent number: 10509043
    Abstract: Provided is a method for identifying pregnancy failure in a subject, the method comprising determining a concentration of at least one element of fetal or embryonic origin in the vaginal fluid of the subject; and comparing the concentration of the at least one element of fetal or embryonic origin to a reference value, wherein when the concentration of the at least one element of fetal or embryonic origin in the vaginal fluid is higher than the reference value, pregnancy failure is indicated.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 17, 2019
    Inventor: Amir Mor
  • Patent number: 10502746
    Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1 or more and an antibody binding to rat IgG2c with an avidity of 9.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: December 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 10495649
    Abstract: The present invention relates to a polypeptide carrying a human BNP(1-32) epitope according to Formula (I): a1-R1—X1—FGRKMDR—X2—R2-a2 as well as ligands specific of the FGRKMDR epitope.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 3, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), BIO-RAD EUROPE GMBH
    Inventors: Francois Rieunier, Isabelle Giuliani, Sylvie Villard-Saussine
  • Patent number: 10488308
    Abstract: The present invention is in the field of in vitro diagnostics and relates to a method for preparing lipemic plasma or serum samples and the use thereof for establishing a lipid interference in the quantitative determination of the amount or the activity of an analyte in a plasma or serum sample.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 26, 2019
    Inventor: Juergen Patzke
  • Patent number: 10480034
    Abstract: The application discloses new biomarkers and methods useful in the diagnosis, prognosis and/or monitoring of, or as a therapeutic or research target for, solid tumour cancers, such as colorectal cancer, based on measuring the biomarkers; and related kits and devices.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: November 19, 2019
    Inventor: Jeffrey Lordan